Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets

Nov 2023| PHM119C| BCC Publishing

Report Highlights

The global market for antithrombotic/anticoagulant drugs is estimated to grow from $31.6 billion in 2023 to reach $46.2 billion by 2028, at a compound annual growth rate (CAGR) of 7.9% from 2023 through 2028.

Report Includes

  • 59 data tables and 35 additional tables
  • Overview and an up-to-date analysis of the global markets for antithrombotic/anticoagulant drugs for the treatments of thrombotic (cardiovascular) disease
  • Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
  • Examination of the market potential for antithrombotic/anticoagulant drugs, and quantification of the global market for these drugs and its market segments and sub-segments over the next five years
  • Estimate of the actual market size and revenue forecast for the market, and corresponding market share analysis based on product type, application and region
  • In-depth information (facts and figures) pertaining to the market drivers, challenges, opportunities and prospects, as well as the technologies, regulatory scenarios and impact of COVID-19
  • A look at the major vendors in the global market for antithrombotic/anticoagulant drugs, and analysis of the healthcare industry structure, including market shares and recent mergers and acquisitions (M&A) activity
  • Review of key patent grants and a look at breakthrough innovations, novel products, upcoming trends and technologies, and emerging applications for cardiovascular treatments
  • Insight into the importance of ESG in the worldwide market, with a look at consumer attitudes, risks and opportunities assessment, and ESG practices followed by manufacturers and service providers
  • Identification of the major stakeholders, and analysis of the competitive landscape based on recent developments, key financials and segmental revenues, and operational integration
  • Profiles of the leading market players

Report Scope

This report discusses the implications of the trends mentioned above in the context of the current size and growth of the antithrombotic/anticoagulant drugs market, in global terms and by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the leading drug categories and the country offers breakdowns of the antithrombotic/anticoagulant drugs market.

Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of major players. The patent analysis focuses on technological trends in recent years in regions such as the U.S., Europe, and Japan. The report presents a market analysis and estimates the compound annual growth rate (CAGR) for the antithrombotic/anticoagulant drugs market.

This report segments the global market by these geographic regions: North America, Europe, Asia-Pacific, and the Rest of the World. For market estimates, data are provided for 2022 as the base year, forecasted through 2023-2028.

Frequently Asked Questions (FAQs)

The antithrombotic/anticoagulant drugs market is projected to grow from $29.4 billion in 2022 to $46.2 billion in 2028 at a compound annual growth rate (CAGR) of 7.9% during the forecast period.
The key factors driving the growth of the antithrombotic/anticoagulant drugs market include increasing research and development and clinical trial activities, the rise in prevalence of cardiovascular and thrombotic diseases, and the growing aging population with peripheral cardiovascular diseases patients is boosting the growth of the antithrombotic/anticoagulant drugs market.
The antithrombotic/anticoagulant drugs market is segmented based on by drug type, and by region.
The Thrombin inhibitors segment will dominate the antithrombotic/anticoagulant drugs market by the end of 2028.
Key companies in the market include Bristol Myers Squibb, Johnson & Johnson Services Inc., Sanofi, Genentech, Boehringer Ingelheim Pharmaceuticals Inc., Bayer, Daiichi Sankyo Co. Ltd., Leo Pharma, Pfizer, and others.

Analyst Credentials

Bejini Sandeep Kumar– Assistant Manager - Life Sciences Research
Sandeep Kumar has over 11 years of experience in pharmaceutical and medical equipment research and consulting. With expertise lying in business research studies, such as industry analysis, strategic and financial analysis, opportunity assessment and competitor intelligence. Sandeep has extensive experience in market research and analysis, specializing in healthcare, medical devices, biotechnology, healthcare IT, pharmaceuticals, and others. He holds a bachelor’s degree in Biotechnology and a Post Graduate degree in Business Management from Liverpool John Moores University (LJMU).

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2023-2028
Base year market size $29.4 billion
Market size forecast $46.2 billion
Growth rate CAGR of 7.9% from 2023 to 2028
Units considered $ Millions
Segments covered By Product Type and Region
Regions covered North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Market Drivers
  • Coagulation Factors Targeted to Reduce CVD
  • The Global Burden of Cardiovascular Disease
  • 2030 Global Burden of Cardiovascular Disease
  • The Global Economic Burden of Cardiovascular Disease
  • Sales Performance of Major Drugs in 2022
Companies studied
  • BAYER AG
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • BRISTOL-MYERS SQUIBB CO.
  • DAIICHI SANKYO CO. LTD.
  • F. HOFFMANN-LA ROCHE LTD.
  • JOHNSON & JOHNSON SERVICES INC.
  • MERCK & CO. INC.
  • PFIZER INC.
  • SANOFI

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets157Free
Chapter- 1: Introduction5Free
Chapter- 2: Summary and Highlights3Free
Chapter- 3: Market Overview28Free
Chapter- 4: Global Market for Anticoagulant Drugs9Free
Chapter- 5: Global Market for Antiplatelet Drugs7Free
Chapter- 6: Global Market for Thrombin Inhibitors6Free
Chapter- 7: Global Market for Antithrombotic/Anticoagulant Drugs by Region13Free
Chapter- 8: Sustainability in the Market for Antithrombotic/Anticoagulant Drugs: An ESG Perspective14Free
Chapter- 9: Clinical Trials and Patent Landscape16Free
Chapter- 10: M&A and Venture Funding Outlook4Free
Chapter- 11: Competitive Landscape7Free
Chapter- 12: Company Profiles43Free
Chapter- 13: Appendix2Free
Published - Sep-2016| Analyst - Anuj Pathak| Code - PHM119B

Report Highlights

The global market for antithrombotic/anticoagulant drugs should reach $27.3 billion by 2021 from $18.9 billion in 2016 at a compound annual growth rate (CAGR) of 7.6%, from 2016 to 2021.

Report Includes

  • An overview of the global market for antithrombotic/anticoagulant drugs, which is changing due to factors such as an aging population, an increase in thrombotic events, and recent advances in pharmaceuticals
  • Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021
  • Breakdowns of the market size of anticoagulants by revenue at manufacturers' sales levels, including low molecular weight heparins and oral anticoagulants, as well as breakdowns of antiplatelets and thrombin inhibitors
  • Discussion of research and development of antithrombotic/anticoagulant treatments
  • Profiles of top leaders in each of the market segments along with companies that are novel or have specific interest to the field
Published - Jan-2013| Analyst - Mary Anne Crandall| Code - PHM119A

Report Highlights

The global anticoagulant drug market was valued at nearly $5.8 billion in 2011 and should reach nearly $5.7 billion in 2012.  Total market value is expected to reach nearly $5.4 billion in 2017 after decreasing at a five-year compound annual growth rate (CAGR) of -1.1%.

Report Includes

  • An overview of the global market for antithrombotic/anticoagulant drugs, which is changing due to factors such as an aging population, an increase in thrombotic events, and recent advances in pharmaceuticals
  • Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017
  • Breakdowns of the market size of anticoagulants by revenue at manufacturers' sales levels, including low molecular weight heparins and oral anticoagulants, as well as breakdowns of antiplatelets and thrombin inhibitors
  • Discussion of research and development of antithrombotic/anticoagulant treatments
  • Comprehensive company profiles of top leaders in each of the market segments along with companies that are novel or have specific interest to the field.
Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets

Single User License: $5500

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.

RELATED REPORTS